Bio-Techne Corporation (TECH) Q4 2025 Earnings Call Transcript
Bio-Techne Corporation (NASDAQ:TECH ) Q4 2025 Earnings Conference Call August 6, 2025 9:00 AM ET Company Participants David Clair - VP of Investor Relations & Corporate Development James T. Hippel - Executive VP of Finance & CFO Kim Kelderman - CEO, President & Director Conference Call Participants Brandon Couillard - Wells Fargo Securities, LLC, Research Division Daniel Markowitz - Evercore ISI Institutional Equities, Research Division Daniel Anthony Arias - Stifel, Nicolaus & Company, Incorporated, Research Division Daniel Louis Leonard - UBS Investment Bank, Research Division Kyle Boucher - TD Cowen, Research Division Matthew Richard Larew - William Blair & Company L.L.C.
Here's What Key Metrics Tell Us About Techne (TECH) Q4 Earnings
The headline numbers for Techne (TECH) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Bio-Techne Q4 Earnings Beat Estimates, Gross Margin Down, Stock Falls
TECH tops Q4 EPS estimates and posts solid revenues, but shrinking margins and operating loss drag shares lower.
Techne (TECH) Beats Q4 Earnings and Revenue Estimates
Techne (TECH) came out with quarterly earnings of $0.53 per share, beating the Zacks Consensus Estimate of $0.5 per share. This compares to earnings of $0.49 per share a year ago.
Bio-Techne beats quarterly estimates on strength in protein sciences unit
Bio-Techne reported better-than-expected fourth-quarter revenue and profit on Wednesday, helped by steady demand for its proteins, antibodies and other products for research.
Bio-Techne Q4 Earnings Preview: What's in Store for the Stock?
TECH eyes modest Q4 growth as strong reagent and instrumentation demand offsets NIH and tariff concerns.
Bio-Techne Q4 Preview: NIH Funding Cut And Tariffs Impacts, Initiate At Sell
Bio-Techne Corporation is a market leader in life science reagents, well positioned for long-term growth in cell and gene therapeutics and organoid solutions. Despite strong fundamentals and recurring revenue, near-term risks from NIH funding cuts and U.S.-China tariffs are not fully priced in. My DCF analysis suggests TECH stock is overvalued, with a fair value of $48 per share versus current high multiples; I initiate with a Sell rating.
Bio-Techne's New USP Deal on mAb and Gene Therapy May Boost Its Stock
TECH teams up with USP to boost mAb and gene therapy testing, aiming to simplify analytics and enhance product quality.
Why Is Techne (TECH) Down 3% Since Last Earnings Report?
Techne (TECH) reported earnings 30 days ago. What's next for the stock?
Is Bio-Techne Stock the Right Pick for Your Portfolio Now?
Bio-Techne's TECH GMP reagents, including GMP proteins and small molecules, remain a cornerstone of its cell therapy offering. Acquisitions have continued to play an important role in the company's efforts to expand its portfolio, as well as enter adjacent markets.
Bio-Techne Q3 Earnings & Revenues Top Estimates, Stock Up in Premarket
TECH registers continued growth momentum across its Diagnostics & Spatial Biology segment in third-quarter fiscal 2025.
Bio-Techne Corporation (TECH) Q3 2025 Earnings Call Transcript
Bio-Techne Corporation (NASDAQ:TECH ) Q3 2025 Earnings Conference Call May 7, 2025 9:00 AM ET Company Participants David Clair - Vice President-Investor Relations Kim Kelderman - President & Chief Executive Officer Jim Hippel - Executive Vice President & Chief Financial Officer Conference Call Participants Puneet Souda - Leerink Partners Dan Leonard - UBS Matt Larew - William Blair Daniel Markowitz - Evercore Dan Arias - Stifel Thomas DeBourcy - Nephron Research Patrick Donnelly - Citi Sung Ji Nam - Scotiabank Operator Good morning and welcome to the Bio-Techne Earnings Conference Call for the Third Quarter of Fiscal Year 2025. At this time, all participants have been placed in a listen-only mode, and the call will be open for questions following the management's prepared remarks.
